AFP and hepatocellular carcinoma: In the current study conducted on 15 patients presented with advanced HCC who were not candidate for surgical or loco regional therapy and after their approval to be enrolled and treated with the defined therapy; they received capecitabine 500 mg per day combined with sorafenib 200 mg twice daily till normalization of AFP then the treatment was modified to give capecitabine 250 mg every other day and sorafenib 400 mg once daily until complete response, progression of disease, unacceptable toxicity.